Table 3 Reasons for discontinuing the drug.
All discontinuations | 66 (100%) |
Ineffectiveness: | 44 (66.7%) |
Primary | 14 (21.2%) |
Secondary | 30 (45.5%) |
Type of ineffectiveness: | |
Peripheral joints | 24 (36.4%) |
Axial | 12 (18.2%) |
Enthesitis | 5 (7.6%) |
Psoriasis | 5 (7.6%) |
Uveitis | 2 (3%) |
Adverse events: | 18 (27.3%) |
Infections | 7 (10.6%) |
Respiratory tract | 4 (6.1%) |
Skin | 1 (1.5%) |
Gastrointestinal tract | 1 (1.5%) |
Opportunistic | 1 (1.5%) |
Neurological | 3 (4.5%) |
Skin lesions | 2 (3%) |
Intolerance | 2 (3%) |
Neoplasm | 2 (3%) |
Allergy | 1 (1.5%) |
Other: | 11 (16.7%) |
Resignation without giving a reason | 5 (7.6%) |
Pregnancy or procreation plans | 3 (4.5%) |
Change of treatment center | 1 (1.5%) |
Administrative reasons | 1 (1.5%) |
Willingness to participate in a clinical trial | 1 (1.5%) |
